Imaging the impact of blood-brain barrier disruption induced by focused ultrasound on P-glycoprotein function
Journal of Controlled Release · 2023
DOI: 10.1016/j.jconrel.2023.08.012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2023. Verfasst von Sébastien Goutal und 12 weiteren Autor:innen. Beteiligte Einrichtung: Laboratoire d'Imagerie Biomédicale Multimodale (BioMaps), Université Paris-Saclay, CEA, CNRS, Inserm, Service Hospitalier Frédéric Joliot, 4 place du…. Hauptthemen laut MEDLINE: ATP Binding Cassette Transporter, Subfamily B, Member 1, Blood-Brain Barrier. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: Agence nationale de la recherche.
Abstract (Originalsprache)
The P-glycoprotein (P-gp/ABCB1) is a major efflux transporter which impedes the brain delivery of many drugs across the blood-brain barrier (BBB). Focused ultrasound with microbubbles (FUS) enables BBB disruption, which immediate and delayed impact on P-gp function remains unclear. Positron emission tomography (PET) imaging using the radiolabeled substrate [11C]metoclopramide provides a sensitive and translational method to study P-gp function at the living BBB. A FUS protocol was devised in rats to induce a substantial and targeted disruption of the BBB in the left hemisphere. BBB disruption was confirmed by the Evan's Blue extravasation test or the minimally-invasive contrast-enhanced MRI. The expression of P-gp was measured 24 h or 48 h after FUS using immunostaining and fluorescence microscopy. The brain kinetics of [11C]metoclopramide was studied by PET at baseline, and both immediately or 24 h after FUS, with or without half-maximum P-gp inhibition (tariquidar 1 mg/kg). In each condition (n = 4-5 rats per group), brain exposure of [11C]metoclopramide was estimated as the area-under-the-curve (AUC) in regions corresponding to the sonicated volume in the left hemisphere, and the contralateral volume. Kinetic modeling was performed to estimate the uptake clearance ratio (R1) of [11C]metoclopramide in the sonicated volume relative to the contralateral volume. In the absence of FUS, half-maximum P-gp inhibition increased brain exposure (+135.0 ± 12.9%, p 0.05). Immediately after FUS, BBB integrity was selectively disrupted in the left hemisphere without any detectable impact on the brain kinetics of [11C]metoclopramide compared with the baseline group (p > 0.05) or the contralateral volume (p > 0.05). 24 h after FUS, BBB integrity was fully restored while P-gp expression was maximally down-regulated (-45.0 ± 4.5%, p 0.05). Only when P-gp was inhibited with tariquidar were the brain exposure (+130 ± 70%) and R1(+29.1 ± 15.4%) significantly increased in the FUS + 24 h/tariquidar group, relative to the baseline group (p < 0.001). We conclude that the brain kinetics of [11C]metoclopramide specifically depends on P-gp function rather than BBB integrity. Delayed FUS-induced down-regulation of P-gp function can be detected. Our results suggest that almost complete down-regulation is required to substantially enhance the brain delivery of P-gp substrates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratoire d'Imagerie Biomédicale Multimodale (BioMaps), Université Paris-Saclay, CEA, CNRS, Inserm, Service Hospitalier Frédéric Joliot, 4 place du Général Leclerc, 91401 Orsay, France.
- Laboratoire d'Imagerie Biomédicale Multimodale (BioMaps), Université Paris-Saclay, CEA, CNRS, Inserm, Service Hospitalier Frédéric Joliot, 4 place du Général Leclerc, 91401 Orsay, France; Université Paris Cité, Inserm,…
- Neurospin, Institut Joliot, Direction de la Recherche Fondamentale, CEA, Université Paris Saclay, Gif sur Yvette, France.
- Université Paris Cité, Inserm, UMRS-1144, Optimisation Thérapeutique en Neuropsychopharmacologie, 75006 Paris, France.
- Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
- Laboratoire d'Imagerie Biomédicale Multimodale (BioMaps), Université Paris-Saclay, CEA, CNRS, Inserm, Service Hospitalier Frédéric Joliot, 4 place du Général Leclerc, 91401 Orsay, France. Electronic address: nicolas.tou…
Förderung
- Agence nationale de la recherche
Zitieren
APA
Goutal, S., Novell, A., Leterrier, S., Breuil, L., Selingue, E., Gerstenmayer, M., Marie, S., Saubaméa, B., Caillé, F., Langer, O., Truillet, C., Larrat, B., & Tournier, N. (2023). Imaging the impact of blood-brain barrier disruption induced by focused ultrasound on P-glycoprotein function. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2023.08.012
Vancouver
Goutal S, Novell A, Leterrier S, Breuil L, Selingue E, Gerstenmayer M, et al. Imaging the impact of blood-brain barrier disruption induced by focused ultrasound on P-glycoprotein function. Journal of Controlled Release. 2023. doi:10.1016/j.jconrel.2023.08.012
BibTeX
@article{Goutal2023,
author = {Goutal, Sébastien and Novell, Anthony and Leterrier, Sarah and Breuil, Louise and Selingue, Erwan and Gerstenmayer, Matthieu and Marie, Solène and Saubaméa, Bruno and Caillé, Fabien and Langer, Oliver and Truillet, Charles and Larrat, Benoît and Tournier, Nicolas},
title = {Imaging the impact of blood-brain barrier disruption induced by focused ultrasound on P-glycoprotein function},
journal = {Journal of Controlled Release},
year = {2023},
doi = {10.1016/j.jconrel.2023.08.012}
}
EUVIMED